The science of rapid start—From the when to the how of antiretroviral initiation

English version České info

In this Perspective linked to Koenig and colleagues, Elvin Geng and Diane Havlir discuss the next challenges for implementation research around rapid start antiretroviral treatment.

Vyšlo v časopise: The science of rapid start—From the when to the how of antiretroviral initiation. PLoS Med 14(7): e32767. doi:10.1371/journal.pmed.1002358
Kategorie: Perspective
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1002358

Souhrn

In this Perspective linked to Koenig and colleagues, Elvin Geng and Diane Havlir discuss the next challenges for implementation research around rapid start antiretroviral treatment.

Zdroje

1. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006,355:2283–2296. doi: 10.1056/NEJMoa062360 17135583

2. Brenchley JM, Price DA, Douek DC. HIV disease: fallout from a mucosal catastrophe? Nature Immunology 2006,7:235–239. doi: 10.1038/ni1316 16482171

3. Deeks SG, Overbaugh J, Phillips A, Buchbinder S. HIV infection. Nature reviews. Disease primers 2014,1:15035–15035.

4. Group TAS. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med 2015,2015:808–822.

5. Zolopa A, Andersen J, Komarow L, Sanne I, Sanchez A, Hogg E, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS ONE 2009,4:e5575. doi: 10.1371/journal.pone.0005575 19440326

6. Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. New England Journal of Medicine 2011,365:1482–1491. doi: 10.1056/NEJMoa1013607 22010914

7. Fowler MG, Qin M, Fiscus SA, Currier JS, Flynn PM, Chipato T, et al. Benefits and risks of antiretroviral therapy for perinatal HIV prevention. New England Journal of Medicine 2016,375:1726–1737. doi: 10.1056/NEJMoa1511691 27806243

8. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. New England journal of medicine 2011,365:493–505. doi: 10.1056/NEJMoa1105243 21767103

9. Fox MP, Rosen S, Geldsetzer P, Bärnighausen T, Negussie E, Beanland R. Interventions to improve the rate or timing of initiation of antiretroviral therapy for HIV in sub-Saharan Africa: meta-analyses of effectiveness. Journal of the International AIDS Society 2016,19.

10. Koenig SP, Dorvil N, Dévieux JG, Hedt-Gauthier BL, Riviere C, Faustin M, et al. Same-Day HIV Testing with Initiation of Antiretroviral Therapy versus Standard Care for Persons Living with HIV: a Randomized Open-Label Trial. PLoS Med. 2017;14(7):e1002357. doi: 10.1371/journal.pmed.1002357

11. Amanyire G, Semitala FC, Namusobya J, Katuramu R, Kampiire L, Wallenta J, et al. Effects of a multicomponent intervention to streamline initiation of antiretroviral therapy in Africa: a stepped-wedge cluster-randomised trial. The Lancet HIV 2016,3:e539–e548. doi: 10.1016/S2352-3018(16)30090-X 27658873

12. Bor J, Fox, M.P., Rosen, S., Venkataramani, A., Tanser, F., Pillary, D., Barnighausen, T. The real world impact of CD4-eligibility criteria on retention in HIV care. In: Conference on Retroviruses and Opportunistic Infections. Seattle; 2016.

13. Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M. The PRECIS-2 tool: designing trials that are fit for purpose. BMJ 2015,350:h2147. doi: 10.1136/bmj.h2147 25956159

14. Tenthani L, Haas AD, Tweya H, Jahn A, van Oosterhout JJ, Chimbwandira F, et al. Retention in care under universal antiretroviral therapy for HIV infected pregnant and breastfeeding women (“Option B+”) in Malawi. AIDS (London, England) 2014,28:589.